Opportunity Information: Apply for PA 25 212
The Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (PA 25-212) is a discretionary grant opportunity from the National Institutes of Health that offers administrative supplement awards to certain active small business awardees. The central purpose of the program is to strengthen commercialization readiness for NIH- and CDC-funded translational technologies by training teams to test and validate a business model through structured, real-world customer discovery. A key restriction is that this opportunity is an administrative supplement mechanism and clinical trials are not allowed under this NOFO.
Eligibility is narrowly targeted to teams that already have active awards in the NIH/CDC small business programs. Specifically, the supplements are intended for active NIH and CDC SBIR awardees and active NIH STTR Phase I awardees. There is also an important timing flexibility: SBIR and STTR Phase I awardees who are in a no-cost extension can still be eligible, but only if the no-cost extension period would cover the entire duration of the selected I-Corps cohort. In practical terms, the underlying Phase I award must remain active for the full training window so the supplement can be administered appropriately. The funding announcement also makes clear that foreign participation is restricted: non-U.S. (foreign) organizations cannot apply, non-U.S. components of U.S. organizations are not eligible, and foreign components (as defined by the NIH Grants Policy Statement) are not allowed.
Programmatically, I-Corps at NIH is designed to move teams beyond a purely technical development mindset and into evidence-based commercialization planning. The mission is to empower entrepreneurs to develop and validate a strategic business model that addresses unmet clinical needs, using broad and diverse customer discovery. The expectation is that teams will engage with stakeholders such as potential users, purchasers, payers, clinical decision-makers, partners, and other market actors to test assumptions about the problem, the value proposition, adoption barriers, and routes to market. The intended result is not just a polished pitch, but a set of validated insights that can meaningfully change the direction of a product strategy when necessary.
The training structure is team-based and built around a three-member project team model. Those teams receive instruction and mentoring intended to accelerate translation of technologies already being developed with NIH and CDC SBIR/STTR support. While the notice emphasizes education and mentoring rather than additional R and D, the supplement is meant to help awardees systematically pressure-test their commercialization approach, clarify who the real customer is, refine the target use case, and understand what evidence (clinical, regulatory, reimbursement, workflow, or economic) will be needed to succeed.
NIH and CDC describe anticipated outcomes in very concrete commercialization terms. Teams that complete the cohort are expected to come out with significantly refined commercialization plans, along with better-grounded decisions about whether to pivot elements of their strategy. A "pivot" in this context can mean narrowing or changing the initial target market, adjusting the product concept to fit stakeholder needs, revising pricing and reimbursement assumptions, changing partnership strategy, or rethinking the pathway to regulatory clearance and adoption. The overall aim is to reduce commercialization risk by replacing internal assumptions with external validation gathered through disciplined customer discovery.
Prospective applicants are strongly encouraged to contact NIH scientific/research staff before applying, which signals that program fit and eligibility details matter and that early conversation can help confirm whether a given Phase I SBIR/STTR project aligns with the cohort expectations and administrative supplement requirements. Administrative details provided in the posting include the agency (NIH), the opportunity number (PA 25-212), the original closing date (2025-01-31), the grant instrument type (grant), and multiple CFDA listings associated with NIH program areas. The posting also lists eligible applicants as public and state-controlled institutions of higher education, but the narrative description makes clear that the operational target audience is active SBIR and eligible STTR Phase I grantees/awardees seeking an administrative supplement to participate in the I-Corps training cohort. For final determinations, applicants are directed to the funding announcement for full eligibility and application requirements.Apply for PA 25 212
- The National Institutes of Health in the education, environment, food and nutrition, health, income security and social services sector is offering a public funding opportunity titled "Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp Clinical Trial NOT Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.083, 93.084, 93.113, 93.121, 93.143, 93.172, 93.173, 93.213, 93.233, 93.242, 93.262, 93.273, 93.279, 93.307, 93.350, 93.351, 93.394, 93.395, 93.837, 93.838, 93.839, 93.840, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, 93.866, 93.867.
- This funding opportunity was created on 2024-10-28.
- Applicants must submit their applications by 2025-01-31. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Public and State controlled institutions of higher education.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the I-Corps at NIH Program for NIH and CDC Translational Research (PA 25-212)?
The Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (PA 25-212) is a discretionary National Institutes of Health (NIH) funding opportunity that provides administrative supplement awards to certain active small business awardees. Its purpose is to strengthen commercialization readiness for NIH- and CDC-funded translational technologies through structured training and mentoring focused on real-world customer discovery and business model validation.
What is the main goal of this program?
The central goal is to help teams move beyond a purely technical development approach and build an evidence-based commercialization plan. Teams are trained to test and validate a business model by engaging real stakeholders and using customer discovery to challenge assumptions about the problem, value proposition, adoption barriers, and routes to market.
What type of funding mechanism is used?
This opportunity is specifically an administrative supplement mechanism. It is not a standalone research grant; it is intended to supplement certain active NIH/CDC small business awards so the team can participate in an I-Corps training cohort.
Are clinical trials allowed under this opportunity?
No. A key restriction in the notice is that clinical trials are not allowed under this NOFO (Notice of Funding Opportunity).
Who is eligible to apply for these administrative supplements?
Eligibility is narrowly targeted. The supplements are intended for:
- Active NIH and CDC SBIR awardees, and
- Active NIH STTR Phase I awardees.
The program is designed for teams that already have active awards in the NIH/CDC small business programs and want to strengthen commercialization readiness for translational technologies supported by those awards.
Can SBIR or STTR Phase I awardees in a no-cost extension apply?
Yes, with an important condition. SBIR and STTR Phase I awardees who are in a no-cost extension may still be eligible, but only if the no-cost extension period covers the entire duration of the selected I-Corps cohort. In practical terms, the underlying Phase I award must remain active for the full training window so the supplement can be administered appropriately.
Does the underlying SBIR/STTR award need to stay active during the I-Corps cohort?
Yes. The posting emphasizes that the Phase I award must remain active for the entire duration of the I-Corps cohort (including when a project is in a no-cost extension), because the I-Corps support is provided through an administrative supplement tied to that active award.
Are foreign organizations eligible to apply?
No. Foreign participation is restricted. The opportunity states that:
- Non-U.S. (foreign) organizations cannot apply,
- Non-U.S. components of U.S. organizations are not eligible, and
- Foreign components (as defined by the NIH Grants Policy Statement) are not allowed.
What does the program require teams to do during training?
Teams are expected to test and validate their commercialization assumptions through structured, real-world customer discovery. This includes engaging with relevant market stakeholders to learn what is true in practice (not just in internal plans) about need, adoption, purchase, payment, and implementation.
Who are examples of stakeholders teams are expected to engage during customer discovery?
The opportunity notes that teams should engage broadly with stakeholders such as potential users, purchasers, payers, clinical decision-makers, partners, and other market actors. The goal is to test assumptions about unmet clinical needs, the value proposition, adoption barriers, and viable routes to market.
Is the expected outcome just a pitch deck or business plan?
No. The notice emphasizes that the intended result is not merely a polished pitch. The focus is on validated insights gained through disciplined customer discovery, including insights that can meaningfully change the direction of a product strategy when needed.
What is meant by a "pivot" in this program?
A pivot refers to a change in commercialization strategy based on what teams learn from external validation. The opportunity describes pivots in concrete terms, such as narrowing or changing the initial target market, adjusting the product concept to better fit stakeholder needs, revising pricing and reimbursement assumptions, changing partnership strategy, or rethinking the pathway to regulatory clearance and adoption.
What kinds of commercialization topics does the training help teams clarify?
Based on the posting, the supplement-supported training and mentoring are intended to help teams:
- Identify who the real customer is,
- Refine the target use case,
- Understand adoption barriers and routes to market, and
- Clarify what evidence may be needed for success (for example, clinical, regulatory, reimbursement, workflow, economic, or related evidence considerations mentioned in the notice).
Is this program intended to fund additional R and D?
The notice emphasizes education and mentoring rather than additional R and D. The administrative supplement is meant to support structured commercialization readiness activities, particularly customer discovery and business model validation, for technologies already being developed with NIH and CDC SBIR/STTR support.
How are teams structured for participation?
The training structure is team-based and built around a three-member project team model. Teams receive instruction and mentoring intended to accelerate translation and commercialization planning for the NIH- or CDC-supported translational technology.
What outcomes are anticipated after completing the I-Corps cohort?
NIH and CDC describe anticipated outcomes in concrete commercialization terms. Teams are expected to complete the cohort with significantly refined commercialization plans and better-grounded decisions about whether to pivot elements of their strategy, with the overall aim of reducing commercialization risk by replacing internal assumptions with external validation.
Are applicants encouraged to contact NIH staff before applying?
Yes. Prospective applicants are strongly encouraged to contact NIH scientific/research staff before applying. This suggests that confirming eligibility, fit with cohort expectations, and alignment with administrative supplement requirements is important and that early communication may help clarify those points.
Which agency is offering this opportunity and what is the opportunity number?
The agency listed is the National Institutes of Health (NIH). The opportunity number provided is PA 25-212.
What was the original closing date listed for this opportunity?
The posting lists an original closing date of 2025-01-31.
What is the grant instrument type?
The administrative details in the posting list the grant instrument type as a grant.
Are there CFDA listings associated with this opportunity?
Yes. The posting notes that there are multiple CFDA listings associated with NIH program areas.
The posting lists eligible applicants as public and state-controlled institutions of higher education. How does that relate to the SBIR/STTR focus described?
Based on the narrative description provided, the operational target audience is active SBIR awardees and eligible STTR Phase I awardees seeking an administrative supplement to participate in the I-Corps training cohort. The posting also notes that applicants should refer to the full funding announcement for complete eligibility and application requirements, indicating that the NOFO should be used for final determinations.
Where should applicants look for final eligibility and application requirements?
For final determinations, the posting directs applicants to the funding announcement (NOFO) for full eligibility and application requirements.
Browse more opportunities from the same category: Education, Environment, Food and Nutrition, Health, Income Security and Social Services
Next opportunity: Somalia - Operational Mentorship SOI
Previous opportunity: Continuation or Revision of NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UH3 Clinical Trial Required)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 25 212
Applicants also applied for:
Applicants who have applied for this opportunity (PA 25 212) also looked into and applied for these:
| Funding Opportunity |
|---|
| Dissemination and Implementation Research in Health (R01 Clinical Trial Optional) Apply for PAR 25 144 Funding Number: PAR 25 144 Agency: National Institutes of Health Category: Education, Environment, Food and Nutrition, Health, Income Security and Social Services Funding Amount: Case Dependent |
| Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed) Apply for PAR 25 134 Funding Number: PAR 25 134 Agency: National Institutes of Health Category: Education, Environment, Food and Nutrition, Health, Income Security and Social Services Funding Amount: $375,000 |
| NIH Research Project Grant (Parent R01 Clinical Trial Required) Apply for PA 25 305 Funding Number: PA 25 305 Agency: National Institutes of Health Category: Education, Environment, Food and Nutrition, Health, Income Security and Social Services Funding Amount: Case Dependent |
| NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) Apply for PA 25 301 Funding Number: PA 25 301 Agency: National Institutes of Health Category: Education, Environment, Food and Nutrition, Health, Income Security and Social Services Funding Amount: Case Dependent |
| NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required) Apply for PA 25 303 Funding Number: PA 25 303 Agency: National Institutes of Health Category: Education, Environment, Food and Nutrition, Health, Income Security and Social Services Funding Amount: Case Dependent |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) Apply for PAR 25 379 Funding Number: PAR 25 379 Agency: National Institutes of Health Category: Education, Environment, Food and Nutrition, Health, Income Security and Social Services Funding Amount: Case Dependent |
| Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed) Apply for PAR 25 414 Funding Number: PAR 25 414 Agency: National Institutes of Health Category: Education, Environment, Food and Nutrition, Health, Income Security and Social Services Funding Amount: $100,000 |
| Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30) Apply for PA 25 425 Funding Number: PA 25 425 Agency: National Institutes of Health Category: Education, Environment, Food and Nutrition, Health, Income Security and Social Services Funding Amount: Case Dependent |
| Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32) Apply for PA 25 423 Funding Number: PA 25 423 Agency: National Institutes of Health Category: Education, Environment, Food and Nutrition, Health, Income Security and Social Services Funding Amount: Case Dependent |
| Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30) Apply for PA 25 426 Funding Number: PA 25 426 Agency: National Institutes of Health Category: Education, Environment, Food and Nutrition, Health, Income Security and Social Services Funding Amount: Case Dependent |
| Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31) Apply for PA 25 422 Funding Number: PA 25 422 Agency: National Institutes of Health Category: Education, Environment, Food and Nutrition, Health, Income Security and Social Services Funding Amount: Case Dependent |
| Support for Research Excellence First Independent Research (SuRE-First) Award (R16 - Clinical Trial Not Allowed) Apply for PAR 25 415 Funding Number: PAR 25 415 Agency: National Institutes of Health Category: Education, Environment, Food and Nutrition, Health, Income Security and Social Services Funding Amount: $125,000 |
| Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed) Apply for PAR 25 322 Funding Number: PAR 25 322 Agency: National Institutes of Health Category: Education, Environment, Food and Nutrition, Health, Income Security and Social Services Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 25 212", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.